← Back to search

CVE-2026-110204

8.8 HIGHpublic exploit available

Published 2026-10-13 · Updated 2026-10-15

AI risk analysis

Summary
Roo Code 3.54.0 contains a command approval bypass vulnerability where parseCommandLine() incorrectly treats ${ command; } substitutions as parameter expansions instead of actual commands, allowing attackers to execute denied shell commands through indirect prompt injection. This affects bash 5.3+ and ksh93 shells.
Exploitability
Exploitation is moderately difficult requiring indirect prompt injection to embed denied commands within allowlisted commands like echo, but the vulnerability is triggerable with user interaction via a web interface.
Blast radius
The vulnerability could allow attackers to execute arbitrary shell commands on affected systems with high privilege, potentially leading to full system compromise if the application runs with elevated permissions.
Detection
No reliable host or network indicator is derivable from the published description.
Prioritized remediation
Upgrade to Roo Code 3.55.0 or later to address the command approval bypass vulnerability.
command-injectionshell-injectionbypass

Analysis generated locally by garnet-coder (no data left the box). AI-assisted — verify against primary sources before acting.

NVD description

Roo Code through 3.54.0 contains a command approval bypass vulnerability that allows attackers to run denied shell commands because parseCommandLine() treats ${ command; } substitutions as parameter expansions. Attackers using indirect prompt injection can embed denied commands inside an allowlisted command like echo to execute them without user approval on bash 5.3+ or ksh93.

CVSS vector

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

Weaknesses

CWE-436

Vendors

roocode

Products

roo code

Public exploit & PoC references

All references

Source data: NVD (nvd.nist.gov), public domain. Exploit-DB.ai adds local AI analysis for defensive use only.

Related CVEs

Related by shared AI tags and CWE weakness class. Browse the full archive.